Grant of Permission to manufacture and market FDC of Naproxen Delayed Release and Esomeprazole capsule (375mg/500mg + 20mg/20mg)
Celecoxib Capsules approval complements Strides’ existing products to serve a broader patient base
Ibuprofen and famotidine combination is indicated for the relief of signs and symptoms of rheumatoid arthritis and osteoarthritis
There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis
Zydus' Indomethacin suppositories also been granted 180-day CGT exclusivity to market this product.
Through the use of robotic assisted orthopaedic surgeries, the success rate is close to 98%
Lilly to further investigate retatrutide for the treatment of obesity in the TRIUMPH phase 3 clinical program
Diclofenac Sodium and Misoprostol Delayed Release Tablets USP, 50mg/200 mcg and 75mg/200 mcg had annual sales of USD 13 mn in the United States
Subscribe To Our Newsletter & Stay Updated